James Investment Research Inc. Takes Position in Lantheus Holdings Inc (NASDAQ:LNTH)

James Investment Research Inc. bought a new position in Lantheus Holdings Inc (NASDAQ:LNTH) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 88,620 shares of the medical equipment provider’s stock, valued at approximately $1,289,000. James Investment Research Inc. owned approximately 0.23% of Lantheus as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in LNTH. Teacher Retirement System of Texas purchased a new stake in Lantheus in the 4th quarter worth approximately $200,000. AMP Capital Investors Ltd acquired a new stake in shares of Lantheus in the 4th quarter worth $205,000. MetLife Investment Advisors LLC acquired a new stake in shares of Lantheus in the 4th quarter worth $267,000. First Trust Advisors LP grew its holdings in shares of Lantheus by 14.1% during the 4th quarter. First Trust Advisors LP now owns 26,523 shares of the medical equipment provider’s stock worth $542,000 after purchasing an additional 3,268 shares during the period. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in shares of Lantheus by 13.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 32,861 shares of the medical equipment provider’s stock worth $672,000 after purchasing an additional 3,841 shares during the period. Institutional investors and hedge funds own 93.06% of the company’s stock.

In other Lantheus news, Director Julie Mchugh sold 4,560 shares of the business’s stock in a transaction on Monday, June 25th. The stock was sold at an average price of $14.72, for a total transaction of $67,123.20. Following the sale, the director now directly owns 14,752 shares in the company, valued at $217,149.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.20% of the stock is currently owned by insiders.

A number of equities analysts have recently weighed in on the company. ValuEngine upgraded Lantheus from a “strong sell” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research cut Lantheus from a “hold” rating to a “sell” rating in a report on Saturday, August 4th. Wells Fargo & Co decreased their price objective on Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 2nd. Credit Suisse Group decreased their price objective on Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, August 2nd. Finally, BidaskClub raised Lantheus from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $23.75.

Lantheus opened at $13.10 on Friday, according to MarketBeat. Lantheus Holdings Inc has a 52 week low of $13.00 and a 52 week high of $24.45. The company has a market cap of $517.05 million, a price-to-earnings ratio of 16.07, a PEG ratio of 1.29 and a beta of 1.28. The company has a current ratio of 3.86, a quick ratio of 3.14 and a debt-to-equity ratio of 5.94.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. Lantheus had a return on equity of 560.19% and a net margin of 37.53%. The company had revenue of $85.60 million for the quarter, compared to the consensus estimate of $87.90 million. During the same period last year, the business posted $0.35 EPS. The company’s revenue was down 3.6% on a year-over-year basis. equities analysts predict that Lantheus Holdings Inc will post 0.87 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Featured Story: Penny Stocks

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply